

Richard LeBlanc

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2389724/publications.pdf>

Version: 2024-02-01

29
papers

944
citations

1040056

9
h-index

552781

26
g-index

29
all docs

29
docs citations

29
times ranked

1488
citing authors

#	ARTICLE	IF	CITATIONS
1	Management of Myeloma Manifestations and Complications: The Cornerstone of Supportive Care: Recommendation of the Canadian Myeloma Research Group (formerly Myeloma Canada Research) <i>Tj ETQq1 1 0.784314 rgBT₁₁/Overlook</i> e41-e56.	0.4	11
2	Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II study. <i>Bone Marrow Transplantation</i> , 2022, 57, 252-260.	2.4	6
3	Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients. <i>British Journal of Cancer</i> , 2022, 126, 718-725.	6.4	21
4	Early free light chain reduction following treatment initiation predicts favorable outcome in intact immunoglobulin myeloma. <i>Blood Cancer Journal</i> , 2022, 12, 3.	6.2	5
5	Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis. <i>Frontiers in Oncology</i> , 2022, 12, 826342.	2.8	3
6	Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group Database. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 608-617.	0.4	4
7	Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database. <i>Current Oncology</i> , 2022, 29, 1575-1582.	2.2	3
8	Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database. <i>British Journal of Haematology</i> , 2022, 198, 93-102.	2.5	3
9	The impact of lenalidomide maintenance on second-line chemotherapy in transplant eligible patients with multiple myeloma. <i>European Journal of Haematology</i> , 2021, 106, 673-681.	2.2	2
10	Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group database. <i>British Journal of Haematology</i> , 2021, 193, 532-541.	2.5	9
11	Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8038-8038.	1.6	6
12	Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed refractory multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2021, 39, 8018-8018.	1.6	13
13	Selinexor containing regimens in patients with multiple myeloma (MM) previously treated with anti-CD38 monoclonal antibodies (±CD38 mAbs).. <i>Journal of Clinical Oncology</i> , 2021, 39, e20020-e20020.	1.6	0
14	Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada. <i>European Journal of Haematology</i> , 2021, 107, 416-427.	2.2	4
15	The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database. <i>Haematologica</i> , 2021, 106, 1733-1736.	3.5	11
16	Selinexor-Based Regimens in Patients with Multiple Myeloma after Prior Anti-B-Cell Maturation Antigen Treatment. <i>Blood</i> , 2021, 138, 2751-2751.	1.4	3
17	Once Weekly Oral Selinexor, Pomalidomide, and Dexamethasone in Relapsed Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 2748-2748.	1.4	8
18	Lenalidomide Dosing and Outcomes in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database. <i>Blood</i> , 2021, 138, 4721-4721.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study. <i>Blood</i> , 2020, 135, 1833-1846.	1.4	42
20	Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8510-8510.	1.6	15
21	Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8530-8530.	1.6	13
22	Newly diagnosed multiple myeloma patients treated with tandem autoallogeneic stem cell transplant have better overall survival with similar outcomes at time of relapse compared to patients who received autologous transplant only. <i>Clinical Transplantation</i> , 2020, 34, e14099.	1.6	4
23	Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database. <i>Blood</i> , 2020, 136, 5-7.	1.4	0
24	Selinexor Shows Synergy in Combination with Pomalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma. <i>Blood</i> , 2016, 128, 3330-3330.	1.4	6
25	Atypical Chronic Lymphocytic Leukemia with CD200 Expression Shares Similar Outcomes to Classical Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 5572-5572.	1.4	4
26	Selinexor in Combination with Bortezomib and Dexamethasone (SdB) Demonstrates Significant Activity in Patients with Refractory Multiple Myeloma (MM) Including Proteasome-Inhibitor Refractory Patients: Results of the Phase I Stomp Trial. <i>Blood</i> , 2016, 128, 977-977.	1.4	15
27	IgD Heavy-Chain Deposition Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 784-790.	6.1	35
28	FIRST study: Updated overall survival (OS) in stem cell transplant (SCT)-ineligible newly diagnosed multiple myeloma (NDMM) patients (pts) treated with continuous lenalidomide plus low-dose dexamethasone (Rd) vs melphalan, prednisone, and thalidomide (MPT).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8524-8524.	1.6	3
29	Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1195-1206.	10.7	695